Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny, Inc.

Progyny, Inc. (NASDAQ:PGNY ) Q2 2025 Earnings Conference Call August 7, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Mark S. Livingston - Chief Financial Officer Michael Sturmer - President Peter Anevski - CEO & Director Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Larsen - BTIG, LLC, Research Division Jailendra P.

Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript

Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.43 per share a year ago.

Progyny (PGNY) Tops Q2 Earnings and Revenue Estimates

Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement

Progyny, Inc. Announces Second Quarter 2025 Results

Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Progyny (PGNY) Earnings Expected to Grow: Should You Buy?

Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings

New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA , maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights.

Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

Progyny (PGNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance

Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering

Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health

The collaboration will enable Amazon customers who are eligible for Progyny services to discover and enroll in fertility, family building, and menopause benefits. The collaboration will enable Amazon customers who are eligible for Progyny services to discover and enroll in fertility, family building, and menopause benefits.

Progyny Joins Amazon's Health Benefits Connector Program as First Women's Health and Family Building Solution

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors.

Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. “As Progyny continues to be at the forefront of women's health, we are proud to welcome two deeply respected clinical leaders whose unique training and lived experience will bring critical insights to our work,” said Dr. Janet Choi, Chief Medical Officer at Progyny.

Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time.

Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference

Progyny, Inc. (NASDAQ:PGNY ) Q1 2025 Results Conference Call May 8, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Pete Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities David Larsen - BTIG Sarah James - Cantor Fitzgerald Operator Good day, ladies and gentlemen, and welcome to the Progyny Inc. First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode and the floor will be opened for questions and comments after the presentation.

Progyny, Inc. (PGNY) Q1 2025 Earnings Call Transcript

Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago.

Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates

Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 (“the first quarter of 2025”) as compared to the three-month period ended March 31, 2024 (“the first quarter of 2024” or “the prior year period”). “We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building,” said Pete Anevski, Chief Executive Officer of Progyny.

Progyny, Inc. Announces First Quarter 2025 Results

Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors?

GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?

Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025.

Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

Real-time stock quote and overview for PGNY